Pharmacotherapeutic study to assess the efficacy of Babula Phala ( Fruit of Acacia arabica Willd.) in Asthikshya (osteoporosis)

Clinical study has obtained Institutional Ethics committee clearance (GAC/VAD/IEC/90/2024, Date-04/02/2024) and registered at Clinical trial Registry of India ICMR, New Delhi, Vide CTRI/2024/09/073536, [Registered on 06/09/2024]. Study single blind clinical trial. 38 patients were enrolled. Among them 32 patients were completed the study. The overall therapeutic assessment revealed that the treatment produced mild to moderate improvement (34%) in most subjects, with 65.62% showing mild and 6.25% showing moderate improvement, while no complete or marked cure was observed. Among individual symptoms, the maximum improvement was seen in Shrama (39.06%), followed by Asthishula (38.54%). Moderate relief was noted in Rukshata (15.63%) and Nakha Vikara (14.06%). Mild improvement was observed in Asthi Sandhi Baddhata (9.38%) and Sandhi Shaithilya (9.37%), while Keshapatana (5.72%) showed minimal improvement. Additionally, the assessment of objective parameters revealed statistically significant improvement after treatment. Serum Calcium (8.90%) showed a highly significant increase, while Bone Mineral Density – BMD (6.36%) exhibited a significant improvement. Overall, the therapy showed better efficacy in reducing Shrama and Asthishula, indicating that the formulation provided beneficial support in managing the symptoms of Asthikshaya (Osteoporosis).